TY - JOUR
T1 - Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease
AU - Maraganore, Demetrius M.
AU - De Andrade, Mariza
AU - Elbaz, Alexis
AU - Farrer, Matthew J.
AU - Ioannidis, John P.
AU - Krüger, Rejko
AU - Rocca, Walter A.
AU - Schneider, Nicole K.
AU - Lesnick, Timothy G.
AU - Lincoln, Sarah J.
AU - Hulihan, Mary M.
AU - Aasly, Jan O.
AU - Ashizawa, Tetsuo
AU - Chartier-Harlin, Marie Christine
AU - Checkoway, Harvey
AU - Ferrarese, Carlo
AU - Hadjigeorgiou, Georgios
AU - Hattori, Nobutaka
AU - Kawakami, Hideshi
AU - Lambert, Jean Charles
AU - Lynch, Timothy
AU - Mellick, George D.
AU - Papapetropoulos, Spiridon
AU - Parsian, Abbas
AU - Quattrone, Aldo
AU - Riess, Olaf
AU - Tan, Eng King
AU - Van Broeckhoven, Christine
PY - 2006/8/9
Y1 - 2006/8/9
N2 - Context: Identification and replication of susceptibility genes for Parkinson disease at the population level have been hampered by small studies with potential biases. α-Synuclein (SNCA) has been one of the most promising susceptibility genes, but large-scale studies have been lacking. Objective: To determine whether allele-length variability in the dinucleotide repeat sequence (REP1) of the SNCA gene promoter is associated with Parkinson disease susceptibility, whether SNCA promoter haplotypes are associated with Parkinson disease, and whether REP1 variability modifies age at onset. Design, Setting, and Participants: We performed a collaborative analysis of individual-level data on SNCA REP1 and flanking markers in patients with Parkinson disease and controls. Study site recruitment, data collection, and analyses were performed between April 5, 2004, and December 31, 2005. Eighteen participating sites of a global genetics consortium provided clinical data. Genotyping was performed for SNCA REP1, -770, and -116 markers at individual sites; however, each site also provided 20 DNA samples for regenotyping centrally. Main Outcome Measures: Measures included estimations of Hardy-Weinberg equilibrium in controls; a test of heterogeneity; analyses for association of single variants or haplotypes; and survival analyses for age at onset. Results: Of the 18 sites, 11 met stringent criteria for concordance with Hardy-Weinberg equilibrium and low genotyping error rate. These 11 sites provided complete data for 2692 cases and 2652 controls. There was no heterogeneity across studies (P>.60). The SNCA REP1 alleles differed in frequency for cases and controls (P>.001). Genotypes defined by the 263 base-pair allele were associated with Parkinson disease (odds ratio, 1.43; 95% confidence interval, 1.22-1.69; P<.001 for trend). Multilocus haplotypes differed in frequency for cases and controls (global score statistic, P<.001). Two-loci haplotypes were associated with Parkinson disease only when they included REP1 as one of the loci. However, genotypes defined by REP1 alleles did not modify age at onset (P=.55). Conclusion: This large-scale collaborative analysis demonstrates that SNCA REP1 allele-length variability is associated with an increased risk of Parkinson disease.
AB - Context: Identification and replication of susceptibility genes for Parkinson disease at the population level have been hampered by small studies with potential biases. α-Synuclein (SNCA) has been one of the most promising susceptibility genes, but large-scale studies have been lacking. Objective: To determine whether allele-length variability in the dinucleotide repeat sequence (REP1) of the SNCA gene promoter is associated with Parkinson disease susceptibility, whether SNCA promoter haplotypes are associated with Parkinson disease, and whether REP1 variability modifies age at onset. Design, Setting, and Participants: We performed a collaborative analysis of individual-level data on SNCA REP1 and flanking markers in patients with Parkinson disease and controls. Study site recruitment, data collection, and analyses were performed between April 5, 2004, and December 31, 2005. Eighteen participating sites of a global genetics consortium provided clinical data. Genotyping was performed for SNCA REP1, -770, and -116 markers at individual sites; however, each site also provided 20 DNA samples for regenotyping centrally. Main Outcome Measures: Measures included estimations of Hardy-Weinberg equilibrium in controls; a test of heterogeneity; analyses for association of single variants or haplotypes; and survival analyses for age at onset. Results: Of the 18 sites, 11 met stringent criteria for concordance with Hardy-Weinberg equilibrium and low genotyping error rate. These 11 sites provided complete data for 2692 cases and 2652 controls. There was no heterogeneity across studies (P>.60). The SNCA REP1 alleles differed in frequency for cases and controls (P>.001). Genotypes defined by the 263 base-pair allele were associated with Parkinson disease (odds ratio, 1.43; 95% confidence interval, 1.22-1.69; P<.001 for trend). Multilocus haplotypes differed in frequency for cases and controls (global score statistic, P<.001). Two-loci haplotypes were associated with Parkinson disease only when they included REP1 as one of the loci. However, genotypes defined by REP1 alleles did not modify age at onset (P=.55). Conclusion: This large-scale collaborative analysis demonstrates that SNCA REP1 allele-length variability is associated with an increased risk of Parkinson disease.
UR - http://www.scopus.com/inward/record.url?scp=33746869343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746869343&partnerID=8YFLogxK
U2 - 10.1001/jama.296.6.661
DO - 10.1001/jama.296.6.661
M3 - Article
C2 - 16896109
AN - SCOPUS:33746869343
SN - 0098-7484
VL - 296
SP - 661
EP - 670
JO - JAMA
JF - JAMA
IS - 6
ER -